Who's Who Legal: Sweden - Life Sciences



MALIN ALBERT Advokatfirman Hammarskiöld & Co Skeppsbron 42, PO Box 2278, Stockholm, SE-103 17, Sweden Tel: +46-8-578 450 07 Mobile: +46-70-238 47 00 Fax: +46 8 578 450 99 malin.albert@hammarskiold.se www.hammarskiold.se

Regarded as one of Sweden's leading authorities within the legal fields of Life Sciences, Malin is a sought-after advisor. Combining many years of experience from advising Life Sciences clients as external counsel, with a unique commercial experience from working in-house at a pharmaceutical company in France, she provides clients with outstanding expert advice which is practical, useful and to the point. She also supports with strategic thinking and pro-active business solutions to help clients meet their goals. Malin heads Hammarskiöld's Life Sciences team.

Malin's work within Life Sciences mainly focuses on regulatory advice, including compliance issues in relation to industry-specific ethical rules, and commercial matters within the pharmaceutical, biotechnology and medical device sectors as well as health and medical care. Over the past years, data privacy issues have also become more important. Due to her sector specific knowledge, Malin is also often retained as expert to support stock market listings of Life Sciences companies.

As a leader in her field, she frequently handles commercial disputes and argues cases against central government agencies before the Administrative Courts in Sweden.

She has ongoing assignments to hold courses, lectures and workshops related to her areas of expertise and she contributes as editor in international publications such as Pharma & Medical Device Regulation by Lexology GTDT and The Law Reviews - The Healthcare Law Review; Edition 6 - Sweden. Regarded as a leading Life Sciences law specialist, Malin is recommended as Next Generation Partner by Legal 500 EMEA 2022.

WWL says: Malin Albert is an eminent name in the life sciences space where she excels thanks to her first-rate commercial skills and service, particularly when it comes to the healthcare and pharmaceuticals industries.